This three-part series focuses on the impact of geographic atrophy (GA) on patients and the specialists who treat them. In the second installment, Dr. Barakat dicusses the methods used to diagnose GA and the role of imaging in the classification of atrophy and prognostication.
This educational activity is supported by Iveric Bio.
Not for credit.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Mark R. Barakat, MD
Director of Clinical Research
Retinal Consultants of Arizona
Clinical Assistant Professor
University of Arizona
College of Medicine - Phoenix
Phoenix, AZ
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Mark R. Barakat, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Adverum Biotech, Alcon, Allergan, Alimera, Bausch + Lomb, Clearside Biomedical, EyePoint Pharmaceuticals, Kodiak Sciences, Genentech, Graybug, Novartis, Ocular Therapeutix, Opthea, Palatin Technologies, and RegenxBio. Grant/Research Support: Adverum Biotech, Annexon Biosciences, Clearside Biomedical, EyePoint Pharmaceuticals, Kodiak Sciences, Gemini Therapeutics, Genentech, Gyroscope Therapeutics, Novartis, Opthea, Oxurion, RegenxBio, ReNeuron, Ribomic, Stealth Biotherapeutics, and Unity Biotechnology. Speaker’s Bureau: Genentech, Novartis, and Regeneron Pharmaceuticals. Stocks/Shareholder: NeuBase and Oxurion.
The Evolve staff, planners, and reviewers have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Iveric Bio.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Eric D. Donnenfeld, MD
Marjan Farid, MD
Jason J. Jones, MD
Eva I. Liang, MD, FACS
Carlton Yuen, MD
Janis T. Eells, Ph.D.
David Boyer, MD
Diana V. Do, MD
Marion Munk, MD, Ph.D
Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications
1.00 program creditMarion Munk, MD, Ph.D
David Boyer, MD
Marion Munk, MD, Ph.D
David Boyer, MD
